1 / 14

Teddy Ryder, 5yrs, 12.5 kg (1922)

Dr. Best & Dr. Banting. Teddy Ryder (1923). Teddy Ryder, 5yrs, 12.5 kg (1922). Teddy Ryder (1923). 1922 2016. The gap(s). Basu et al. DTT, 2016. Phosphorescence-based Continuous Single-Port Glucose Sensing onto a Commercial Insulin Infusion Set in Subcutaneous Tissue.

josek
Download Presentation

Teddy Ryder, 5yrs, 12.5 kg (1922)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dr. Best & Dr. Banting Teddy Ryder (1923) Teddy Ryder, 5yrs, 12.5 kg (1922) Teddy Ryder (1923)

  2. 1922 2016

  3. The gap(s) Basu et al. DTT, 2016

  4. Phosphorescence-based Continuous Single-Port Glucose Sensing onto a Commercial Insulin Infusion Set in Subcutaneous Tissue M. Rumpler, M. Hajnsek, I. Klimant, F. Sinner Asolution !? JOANNEUM RESEARCH ForschungsgesellschaftmbH HEALTH – Institute for Biomedicine and Health Sciences Medical University of Graz, Austria Division of Endocrinology and Diabetology Graz University of Technology, Graz Austria Institute of Analytical Chemistry and Food Chemistry Graz, 22.03.2016

  5. Technical background LED‘s PD‘s 0.4 mm oxygensensor glucosesensor 7.0 mm

  6. Technical background oxygensensor referencedyelayer (tbutPtNTBP) λabs: 637 nm λem: 860 nm glucosesensor Δ pO2 ~ cglucose glucosedyelayer (PtTPTBPF) λabs: 617 nm λem: 775 nm GOxlayer diffusionlayer

  7. In-vitro results 0.288 ±0.288 mmHg/h n=3 n=6

  8. Clinical trial • First-in-man study of this type of sensor concept • Primary objective To assess the accuracy and reliability of the single-port system with regard to blood reference values (Super GL2, Hitado)

  9. Clinical trial • Single-center, open-label, non-controlled clinical trial • Study design Day1: 9:00 sensor insertion (2x) Day 2: 8:00 reader mounted 20:00 study end reference blood samples every 5 min

  10. Clinical trial – total outcome • Results • 12 patients -> 23 sensors (1 accidently pulled out during day1) • retrospective glucose calculation • Median-ARD: 22.5% (n=960) • fabricated by manual drop-coating • no filtering or correction algorithm

  11. Clinical trial – exemplary outcome Median-ARD 11.8% (n = 41) Median-ARD 7.9% (n = 42)

  12. Conclusion • Successful integration of a CGM system on a CSII set creating a single-port system. • The single-port systemoffers great potential for an artificial pancreas (SPIDIMAN)

  13. Outlook • Optimized/reproducible sensor production • Optimizing sensor calibration / glucose calculation • Clinical trial with active insulin infusion • Combining the single-port system with an insulin calculating algorithm.

  14. Thank you for your attention Markus Rumpler, BSc, MSc mail: ca.health@joanneum.at JOANNEUM RESEARCH ForschungsgesellschaftmbH HEALTH – Institute for Biomedicine and Health Sciences NeueStiftingtalstraße 2, 8010 Graz www.joanneum.at/health Prof. Klimant & Team

More Related